FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1917242018> ?p ?o ?g. }

• W1917242018 abstract "Background Despite the development of new treatment options, the prognosis of high‐risk neuroblastoma patients is still poor; more than half of patients experience disease recurrence. High‐dose chemotherapy and haematopoietic stem cell rescue (i.e. myeloablative therapy) might improve survival. This review is the second update of a previously published Cochrane review. Objectives Primary objective To compare the efficacy, that is event‐free and overall survival, of high‐dose chemotherapy and autologous bone marrow or stem cell rescue with conventional therapy in children with high‐risk neuroblastoma. Secondary objectives To determine adverse effects (e.g. veno‐occlusive disease of the liver) and late effects (e.g. endocrine disorders or secondary malignancies) related to the procedure and possible effects of these procedures on quality of life. Search methods We searched the electronic databases The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, issue 11), MEDLINE/PubMed (1966 to December 2014) and EMBASE/Ovid (1980 to December 2014). In addition, we searched reference lists of relevant articles and the conference proceedings of the International Society for Paediatric Oncology (SIOP) (from 2002 to 2014), American Society for Pediatric Hematology and Oncology (ASPHO) (from 2002 to 2014), Advances in Neuroblastoma Research (ANR) (from 2002 to 2014) and American Society for Clinical Oncology (ASCO) (from 2008 to 2014). We searched for ongoing trials by scanning the ISRCTN register (www.isrct.com) and the National Institute of Health Register (www.clinicaltrials.gov). Both registers were screened in April 2015. Selection criteria Randomised controlled trials (RCTs) comparing the efficacy of myeloablative therapy with conventional therapy in high‐risk neuroblastoma patients. Data collection and analysis Two authors independently performed study selection, data extraction and risk of bias assessment. If appropriate, we pooled studies. The risk ratio (RR) and 95% confidence interval (CI) was calculated for dichotomous outcomes. For the assessment of survival data, we calculated the hazard ratio (HR) and 95% CI. We used Parmar's method if hazard ratios were not reported in the study. We used a random‐effects model. Main results We identified three RCTs including 739 children. They all used an age of one year as the cut‐off point for pre‐treatment risk stratification. The first updated search identified a manuscript reporting additional follow‐up data for one of these RCTs, while the second update identified an erratum of this study. There was a significant statistical difference in event‐free survival in favour of myeloablative therapy over conventional chemotherapy or no further treatment (three studies, 739 patients; HR 0.78, 95% CI 0.67 to 0.90). There was a significant statistical difference in overall survival in favour of myeloablative therapy over conventional chemotherapy or no further treatment (two studies, 360 patients; HR 0.74, 95% CI 0.57 to 0.98). However, when additional follow‐up data were included in the analyses the difference in event‐free survival remained statistically significant (three studies, 739 patients; HR 0.79, 95% CI 0.70 to 0.90), but the difference in overall survival was no longer statistically significant (two studies, 360 patients; HR 0.86, 95% CI 0.73 to 1.01). The meta‐analysis of secondary malignant disease and treatment‐related death did not show any significant statistical differences between the treatment groups. Data from one study (379 patients) showed a significantly higher incidence of renal effects, interstitial pneumonitis and veno‐occlusive disease in the myeloablative group compared to conventional chemotherapy, whereas for serious infections and sepsis no significant difference between the treatment groups was identified. No information on quality of life was reported. In the individual studies we evaluated different subgroups, but the results were not univocal in all studies. All studies had some methodological limitations. Authors' conclusions Based on the currently available evidence, myeloablative therapy seems to work in terms of event‐free survival. For overall survival there is currently no evidence of effect when additional follow‐up data are included. No definitive conclusions can be made regarding adverse effects and quality of life, although possible higher levels of adverse effects should be kept in mind. A definitive conclusion regarding the effect of myeloablative therapy in different subgroups is not possible. This systematic review only allows a conclusion on the concept of myeloablative therapy; no conclusions can be made regarding the best treatment strategy. Future trials on the use of myeloablative therapy for high‐risk neuroblastoma should focus on identifying the most optimal induction and/or myeloablative regimen. The best study design to answer these questions is a RCT. These RCTs should be performed in homogeneous study populations (e.g. stage of disease and patient age) and have a long‐term follow‐up. Different risk groups, using the most recent definitions, should be taken into account. It should be kept in mind that recently the age cut‐off for high risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate‐risk disease have been included in the high‐risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned. Survival rates may be overestimated due to the inclusion of patients with intermediate‐risk disease." @default.
• W1917242018 created "2016-06-24" @default.
• W1917242018 creator A5009565385 @default.
• W1917242018 creator A5029704913 @default.
• W1917242018 creator A5065228177 @default.
• W1917242018 date "2015-10-05" @default.
• W1917242018 modified "2023-10-17" @default.
• W1917242018 title "High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma" @default.
• W1917242018 cites W1587500463 @default.
• W1917242018 cites W1598602811 @default.
• W1917242018 cites W1618716954 @default.
• W1917242018 cites W1810885877 @default.
• W1917242018 cites W1877527541 @default.
• W1917242018 cites W1898762201 @default.
• W1917242018 cites W1910480474 @default.
• W1917242018 cites W1926885922 @default.
• W1917242018 cites W1935834387 @default.
• W1917242018 cites W1965672398 @default.
• W1917242018 cites W1970750346 @default.
• W1917242018 cites W1996695338 @default.
• W1917242018 cites W1996932065 @default.
• W1917242018 cites W1999686443 @default.
• W1917242018 cites W2004748996 @default.
• W1917242018 cites W2012219845 @default.
• W1917242018 cites W2017801710 @default.
• W1917242018 cites W2018538091 @default.
• W1917242018 cites W2027657181 @default.
• W1917242018 cites W2043955976 @default.
• W1917242018 cites W2045831286 @default.
• W1917242018 cites W2046335521 @default.
• W1917242018 cites W2049239353 @default.
• W1917242018 cites W2051406185 @default.
• W1917242018 cites W2052312848 @default.
• W1917242018 cites W2066098786 @default.
• W1917242018 cites W2066101699 @default.
• W1917242018 cites W2075642745 @default.
• W1917242018 cites W2086226581 @default.
• W1917242018 cites W2088130748 @default.
• W1917242018 cites W2088302148 @default.
• W1917242018 cites W2096398040 @default.
• W1917242018 cites W2096539632 @default.
• W1917242018 cites W2111348128 @default.
• W1917242018 cites W2113695682 @default.
• W1917242018 cites W2114635357 @default.
• W1917242018 cites W2125435699 @default.
• W1917242018 cites W2129463829 @default.
• W1917242018 cites W2130465135 @default.
• W1917242018 cites W2135444901 @default.
• W1917242018 cites W2136574608 @default.
• W1917242018 cites W2138216545 @default.
• W1917242018 cites W2147800896 @default.
• W1917242018 cites W2152420890 @default.
• W1917242018 cites W2157124382 @default.
• W1917242018 cites W2157272402 @default.
• W1917242018 cites W2157641729 @default.
• W1917242018 cites W2157952351 @default.
• W1917242018 cites W2164097016 @default.
• W1917242018 cites W2168218956 @default.
• W1917242018 cites W2257281028 @default.
• W1917242018 cites W2264275593 @default.
• W1917242018 cites W2269641212 @default.
• W1917242018 cites W2280912529 @default.
• W1917242018 cites W2327522594 @default.
• W1917242018 cites W2329260870 @default.
• W1917242018 cites W2333564721 @default.
• W1917242018 cites W4211031423 @default.
• W1917242018 cites W4211182915 @default.
• W1917242018 cites W4229763785 @default.
• W1917242018 cites W4234309009 @default.
• W1917242018 cites W4252079245 @default.
• W1917242018 doi "https://doi.org/10.1002/14651858.cd006301.pub4" @default.
• W1917242018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26436598" @default.
• W1917242018 hasPublicationYear "2015" @default.
• W1917242018 type Work @default.
• W1917242018 sameAs 1917242018 @default.
• W1917242018 citedByCount "63" @default.
• W1917242018 countsByYear W19172420182012 @default.
• W1917242018 countsByYear W19172420182013 @default.
• W1917242018 countsByYear W19172420182014 @default.
• W1917242018 countsByYear W19172420182015 @default.
• W1917242018 countsByYear W19172420182016 @default.
• W1917242018 countsByYear W19172420182017 @default.
• W1917242018 countsByYear W19172420182018 @default.
• W1917242018 countsByYear W19172420182019 @default.
• W1917242018 countsByYear W19172420182020 @default.
• W1917242018 countsByYear W19172420182021 @default.
• W1917242018 countsByYear W19172420182022 @default.
• W1917242018 countsByYear W19172420182023 @default.
• W1917242018 crossrefType "journal-article" @default.
• W1917242018 hasAuthorship W1917242018A5009565385 @default.
• W1917242018 hasAuthorship W1917242018A5029704913 @default.
• W1917242018 hasAuthorship W1917242018A5065228177 @default.
• W1917242018 hasBestOaLocation W19172420181 @default.
• W1917242018 hasConcept C126322002 @default.
• W1917242018 hasConcept C143998085 @default.
• W1917242018 hasConcept C168563851 @default.
• W1917242018 hasConcept C197934379 @default.
• W1917242018 hasConcept C2776478404 @default.
• W1917242018 hasConcept C71924100 @default.
• W1917242018 hasConceptScore W1917242018C126322002 @default.

• next